$BMRA First things first: Absolutely gutted. Truly believed the rapid tests were being used as a tool for fighting this pandemic and shocked at it’s limited demand and limited use thus far. Second: The ELISA test is verrrrrry different from the rapid test. It’s what we’ve been waiting for and counting on for months and is still on track. Still has $35M+/mo. revenue potential and critical for pairing with vaccine research and efficacy. Third: InFoods is still and has always been the millionaire-maker, and waiting in the wings. Will impact stock positively even before pivotal trials is it will likely be licensed out after clinical trials. Lock in your loss if you need to, but all the main pillars are still standing here.
  • 4
4 Likes